Market capitalization | $3.01b |
Enterprise Value | $2.94b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 28.93 |
P/S ratio (TTM) P/S ratio | 29.58 |
P/B ratio (TTM) P/B ratio | 76.48 |
Revenue growth (TTM) Revenue growth | 132.57% |
Revenue (TTM) Revenue | $101.78m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
9 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:
9 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 102 102 |
133%
133%
|
|
Gross Profit | 90 90 |
138%
138%
|
|
EBITDA | -264 -264 |
48%
48%
|
EBIT (Operating Income) EBIT | -266 -266 |
47%
47%
|
Net Profit | -259 -259 |
42%
42%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Head office | United States |
CEO | David Meeker |
Employees | 226 |
Founded | 2008 |
Website | www.rhythmtx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.